Clinical features and outcomes of myelodysplastic syndrome patients with iron overload: a single-center retrospective study

Abstract Objectives Most of the myelodysplastic syndromes (MDS) patients suffer from iron overload (IOL) due to ineffective hematopoiesis and repeated blood transfusions. IOL may affect the survival of MDS patients, but the related mechanism has not been fully clarified. We aimed to provide clinical...

Full description

Saved in:
Bibliographic Details
Main Authors: Lei Huang, Yinxing Wang, Xinrui Zhang, Xintong Xu, Ziqi Zhang, XinRu Wu, Chunyan Liu, Rong Fu
Format: Article
Language:English
Published: BMC 2025-07-01
Series:European Journal of Medical Research
Subjects:
Online Access:https://doi.org/10.1186/s40001-025-02848-1
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849237582839283712
author Lei Huang
Yinxing Wang
Xinrui Zhang
Xintong Xu
Ziqi Zhang
XinRu Wu
Chunyan Liu
Rong Fu
author_facet Lei Huang
Yinxing Wang
Xinrui Zhang
Xintong Xu
Ziqi Zhang
XinRu Wu
Chunyan Liu
Rong Fu
author_sort Lei Huang
collection DOAJ
description Abstract Objectives Most of the myelodysplastic syndromes (MDS) patients suffer from iron overload (IOL) due to ineffective hematopoiesis and repeated blood transfusions. IOL may affect the survival of MDS patients, but the related mechanism has not been fully clarified. We aimed to provide clinical evidence for the impact of IOL on the immunity and prognosis of MDS patients. Methods The clinical features and outcomes of 144 patients with MDS between March 2019 and December 2023 were analyzed. Patients were classified into the IOL group (ferritin > 1000 ng/mL) and the non-iron overload (NIOL) group (ferritin ≤ 1000 ng/mL). Results The median age of the patients was 64 (22–89) years, and IOL MDS patients had a poorer performance status. IOL MDS patients had significantly higher alanine aminotransferase and blood glucose levels. White blood cell counts and hemoglobin levels were significantly lower in IOL MDS patients. Meanwhile, the proportion of erythrocyte and megakaryocyte counts were significantly decreased in MDS patients with IOL. The incidence of 7q- chromosome abnormalities in IOL group was significantly higher. The level of Interleukin-6 was markedly elevated in patients with IOL MDS, accompanied by significant abnormalities in dendritic cells. Survival analysis indicated that IOL MDS patients had a shorter survival duration. Age ≥ 60 years, ferritin > 1000 ng/mL, complex chromosomal abnormalities, and gene mutations in TP53 and RUNX1 were independent adverse prognostic factors for MDS patients. Conclusions IOL MDS patients exhibit poorer performance status and organ function, with hematopoietic and immune function abnormalities potentially affecting their survival.
format Article
id doaj-art-01979a88e2c94de48ade32376eca0095
institution Kabale University
issn 2047-783X
language English
publishDate 2025-07-01
publisher BMC
record_format Article
series European Journal of Medical Research
spelling doaj-art-01979a88e2c94de48ade32376eca00952025-08-20T04:01:56ZengBMCEuropean Journal of Medical Research2047-783X2025-07-0130111110.1186/s40001-025-02848-1Clinical features and outcomes of myelodysplastic syndrome patients with iron overload: a single-center retrospective studyLei Huang0Yinxing Wang1Xinrui Zhang2Xintong Xu3Ziqi Zhang4XinRu Wu5Chunyan Liu6Rong Fu7Department of Hematology, Tianjin Medical University General HospitalDepartment of Hematology, Tianjin Medical University General HospitalDepartment of Hematology, Tianjin Medical University General HospitalDepartment of Hematology, Tianjin Medical University General HospitalDepartment of Hematology, Tianjin Medical University General HospitalDepartment of Hematology, Tianjin Medical University General HospitalDepartment of Hematology, Tianjin Medical University General HospitalDepartment of Hematology, Tianjin Medical University General HospitalAbstract Objectives Most of the myelodysplastic syndromes (MDS) patients suffer from iron overload (IOL) due to ineffective hematopoiesis and repeated blood transfusions. IOL may affect the survival of MDS patients, but the related mechanism has not been fully clarified. We aimed to provide clinical evidence for the impact of IOL on the immunity and prognosis of MDS patients. Methods The clinical features and outcomes of 144 patients with MDS between March 2019 and December 2023 were analyzed. Patients were classified into the IOL group (ferritin > 1000 ng/mL) and the non-iron overload (NIOL) group (ferritin ≤ 1000 ng/mL). Results The median age of the patients was 64 (22–89) years, and IOL MDS patients had a poorer performance status. IOL MDS patients had significantly higher alanine aminotransferase and blood glucose levels. White blood cell counts and hemoglobin levels were significantly lower in IOL MDS patients. Meanwhile, the proportion of erythrocyte and megakaryocyte counts were significantly decreased in MDS patients with IOL. The incidence of 7q- chromosome abnormalities in IOL group was significantly higher. The level of Interleukin-6 was markedly elevated in patients with IOL MDS, accompanied by significant abnormalities in dendritic cells. Survival analysis indicated that IOL MDS patients had a shorter survival duration. Age ≥ 60 years, ferritin > 1000 ng/mL, complex chromosomal abnormalities, and gene mutations in TP53 and RUNX1 were independent adverse prognostic factors for MDS patients. Conclusions IOL MDS patients exhibit poorer performance status and organ function, with hematopoietic and immune function abnormalities potentially affecting their survival.https://doi.org/10.1186/s40001-025-02848-1Myelodysplastic syndromeIron overloadHematopoiesisImmune indexPrognosis
spellingShingle Lei Huang
Yinxing Wang
Xinrui Zhang
Xintong Xu
Ziqi Zhang
XinRu Wu
Chunyan Liu
Rong Fu
Clinical features and outcomes of myelodysplastic syndrome patients with iron overload: a single-center retrospective study
European Journal of Medical Research
Myelodysplastic syndrome
Iron overload
Hematopoiesis
Immune index
Prognosis
title Clinical features and outcomes of myelodysplastic syndrome patients with iron overload: a single-center retrospective study
title_full Clinical features and outcomes of myelodysplastic syndrome patients with iron overload: a single-center retrospective study
title_fullStr Clinical features and outcomes of myelodysplastic syndrome patients with iron overload: a single-center retrospective study
title_full_unstemmed Clinical features and outcomes of myelodysplastic syndrome patients with iron overload: a single-center retrospective study
title_short Clinical features and outcomes of myelodysplastic syndrome patients with iron overload: a single-center retrospective study
title_sort clinical features and outcomes of myelodysplastic syndrome patients with iron overload a single center retrospective study
topic Myelodysplastic syndrome
Iron overload
Hematopoiesis
Immune index
Prognosis
url https://doi.org/10.1186/s40001-025-02848-1
work_keys_str_mv AT leihuang clinicalfeaturesandoutcomesofmyelodysplasticsyndromepatientswithironoverloadasinglecenterretrospectivestudy
AT yinxingwang clinicalfeaturesandoutcomesofmyelodysplasticsyndromepatientswithironoverloadasinglecenterretrospectivestudy
AT xinruizhang clinicalfeaturesandoutcomesofmyelodysplasticsyndromepatientswithironoverloadasinglecenterretrospectivestudy
AT xintongxu clinicalfeaturesandoutcomesofmyelodysplasticsyndromepatientswithironoverloadasinglecenterretrospectivestudy
AT ziqizhang clinicalfeaturesandoutcomesofmyelodysplasticsyndromepatientswithironoverloadasinglecenterretrospectivestudy
AT xinruwu clinicalfeaturesandoutcomesofmyelodysplasticsyndromepatientswithironoverloadasinglecenterretrospectivestudy
AT chunyanliu clinicalfeaturesandoutcomesofmyelodysplasticsyndromepatientswithironoverloadasinglecenterretrospectivestudy
AT rongfu clinicalfeaturesandoutcomesofmyelodysplasticsyndromepatientswithironoverloadasinglecenterretrospectivestudy